Compare Cipla with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TORRENT PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA TORRENT PHARMA CIPLA/
TORRENT PHARMA
 
P/E (TTM) x 23.4 58.5 40.0% View Chart
P/BV x 2.4 6.2 38.6% View Chart
Dividend Yield % 0.7 0.8 81.3%  

Financials

 CIPLA   TORRENT PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
TORRENT PHARMA
Mar-18
CIPLA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6781,550 43.7%   
Low Rs4841,144 42.3%   
Sales per share (Unadj.) Rs198.2354.7 55.9%  
Earnings per share (Unadj.) Rs18.540.1 46.2%  
Cash flow per share (Unadj.) Rs35.064.2 54.5%  
Dividends per share (Unadj.) Rs3.0014.00 21.4%  
Dividend yield (eoy) %0.51.0 49.7%  
Book value per share (Unadj.) Rs186.3273.1 68.2%  
Shares outstanding (eoy) m805.70169.22 476.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.93.8 77.2%   
Avg P/E ratio x31.433.6 93.3%  
P/CF ratio (eoy) x16.621.0 79.2%  
Price / Book Value ratio x3.14.9 63.2%  
Dividend payout %16.234.9 46.4%   
Avg Mkt Cap Rs m468,031227,897 205.4%   
No. of employees `00022.614.7 154.0%   
Total wages/salary Rs m28,56511,353 251.6%   
Avg. sales/employee Rs Th7,053.14,083.0 172.7%   
Avg. wages/employee Rs Th1,261.5772.3 163.3%   
Avg. net profit/employee Rs Th659.1461.3 142.9%   
INCOME DATA
Net Sales Rs m159,71060,021 266.1%  
Other income Rs m4,7662,988 159.5%   
Total revenues Rs m164,47563,009 261.0%   
Gross profit Rs m30,97313,493 229.6%  
Depreciation Rs m13,2634,086 324.6%   
Interest Rs m1,6843,085 54.6%   
Profit before tax Rs m20,7919,310 223.3%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6952,529 225.2%   
Profit after tax Rs m14,9246,781 220.1%  
Gross profit margin %19.422.5 86.3%  
Effective tax rate %27.427.2 100.9%   
Net profit margin %9.311.3 82.7%  
BALANCE SHEET DATA
Current assets Rs m124,26652,623 236.1%   
Current liabilities Rs m37,71552,022 72.5%   
Net working cap to sales %54.21.0 5,407.6%  
Current ratio x3.31.0 325.7%  
Inventory Days Days91120 75.8%  
Debtors Days Days9576 124.4%  
Net fixed assets Rs m105,19085,016 123.7%   
Share capital Rs m1,611846 190.4%   
"Free" reserves Rs m148,51145,376 327.3%   
Net worth Rs m150,12346,222 324.8%   
Long term debt Rs m38,30141,115 93.2%   
Total assets Rs m239,633142,432 168.2%  
Interest coverage x13.34.0 332.1%   
Debt to equity ratio x0.30.9 28.7%  
Sales to assets ratio x0.70.4 158.2%   
Return on assets %6.96.9 100.1%  
Return on equity %9.914.7 67.8%  
Return on capital %11.814.2 83.4%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41014,580 393.8%   
Fx outflow Rs m19,0413,600 528.9%   
Net fx Rs m38,36810,980 349.4%   
CASH FLOW
From Operations Rs m16,9118,942 189.1%  
From Investments Rs m-16,687-47,070 35.5%  
From Financial Activity Rs m-3,48734,174 -10.2%  
Net Cashflow Rs m-3,451-3,655 94.4%  

Share Holding

Indian Promoters % 16.0 71.5 22.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 7.0 173.8%  
FIIs % 23.7 12.6 188.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.8 297.7%  
Shareholders   161,166 26,511 607.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SUN PHARMA  PFIZER  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 14, 2019 01:17 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS